Society for Laboratory Automation and Screening (SLAS) Europe 2025

Attending SLAS Europe 2025 was not just a showcase opportunity for EFEVRE TECH's proposed VITALE software platform project, it was a milestone in building deeper connections with the academic and scientific community across Europe and beyond, allowing us to build a strong ground for market-readiness. While presenting our work on VITALE, our team actively engaged with researchers, principal investigators, and biomedical innovation experts from leading institutions and research laboratories.

Academic Interest in VITALE’s AI-Powered Approach

Our scientific poster on the automated detection of clonal hematopoiesis using VITALE and AMGEL4TT attracted particular attention from the scientific and academic audience specializing in genomics and clinical research. Many researchers expressed interest in the AI-driven literature matching capabilities of VITALE and how it could support evidence-based experiment validation, which is a challenge frequently encountered in data-rich laboratory environments.

Through discussions, it was highlighted that bridging automation hardware with intelligent software would be a strong market-competitor, which would set a new standard for genomic workflow reproducibility and speed.​  These discussions opened the door for several collaboration inquiries, especially from academic laboratories looking to enhance reproducibility in NGS pipelines, to automate documentation for research compliance, and to test VITALE in the context of gene expression, rare variant detection, or epigenetic workflows. Key discussions include:

• Life Science Nord Management GmbH (lifesciencenord.de): As a cluster representing multiple biotech institutions, Life Science Nord opened up pathways for introducing VITALE and AMGEL to their affiliated labs. A follow-up introduction campaign is underway to promote our automation capabilities to new life-science clients through their network.

• Charles River Laboratories (www.criver.com) & Pheranos Pharmaceuticals (www.phenaros.com): Both organizations expressed strong interest in integrating AI-powered automation into their 3D cell culture and pharmaceutical R&D workflows. Follow-up discussions are ongoing, with white-label or co-automation potential under evaluation.

• CELLENION (www.cellenion.com) and Hamilton (www.hamiltoncompany.com): We discussed possible alignment for AMGEL-controlled automation modules and software OEM licensing with these OEMs leaders, which will give a new unique value to the VITALE software, strengthening its market-position and competitiveness. Technical brochures and pricing inquiries have been shared amongst us, with next steps including software demo coordination and NDA exchanges.

• MYXOTECH (myxotech.com) and Nanovery (nanovery.co.uk): Early-stage innovation companies showed interest in the AI-powered software, VITALE, along with the integration for the automation hardware for microbiology and nanorobotics research automation. Though still in scaling phases, both teams requested brochures and suggested revisiting collaboration opportunities during their next funding rounds.

• ANALYTIK JENA GmbH (www.analytik-jena.de) and SPT Labtech (www.sptlabtech.com): Meetings with senior engineers and laboratory automation leads focused on PCR automation compatibility and future co-development. NDAs have been initiated, and demo sessions are scheduled for late June.

• Beckman Coulter Life Sciences (www.beckman.com) and MORE.SCIENCE (more.science): These discussions centered around advanced kit integration and organoid automation. While still early, the technical alignment with VITALE's modular backend and AI layer sparked interest in potential OEM customization.

These meetings yielded more than partnership leads, they offered deep technical insights into what research users need from intelligent automation tools, as well as valuable connections with academic and scientist leaders. Many teams highlighted the importance of modular AI integration, regulatory adaptability, and scientific reproducibility, all areas where VITALE is designed for.

Exploring VITALE: Hands-On Demonstrations and Scientific Dialogue

Society for Laboratory Automation and Screening (SLAS) Europe 2025 served as a powerful launchpad for VITALE, especially due to its scientific and academic-oriented audience attending. Marios Konstantinou’s presentation along with Dr. Dimitris Kyriakou's attendance as an expert researcher, ignited arranged and also walk-in cross-disciplinary conversations about the value of flexible automation, and how the integration of VITALE into AMGEL4TT positions it as a game-changer in life-science laboratories.

This exposure triggered interest from potential collaborators and early adopters, affirming the relevance of VITALE in today’s fast-evolving biomedical landscape. The presentation helped validate our approach to modular automation and intelligent software control, an approach that’s now drawing attention across Europe’s research and diagnostic sectors.

Our presence at SLAS Europe 2025 wasn’t just a showcase, it was a strategic catalyst. The insights and connections gained at this event have helped us refine user feedback loops, attract new collaborators, and better position the VITALE-AMGEL4TT duo for commercialization and clinical piloting.

The response to our poster entitled "Versatile Automation for IVDR Method Development in CH Detection" was overwhelmingly positive. Attendees recognized its alignment with the urgent clinical need for scalable Clonal Hematopoiesis (CH) detection, especially in the context of acute myeloid leukemia (AML) and cardiovascular risk stratification.

Looking Ahead: Building Scientific Trust, One Connection at a Time

This milestone event marked a turning point for the proposed VITALE project. By engaging with Europe’s leading scientists, innovators, and thought leaders, we are now better equipped to move from TRL 4 to TRL 6, expanding clinical testing while ensuring regulatory alignment and scientific robustness. SLAS Europe 2025 reaffirmed our belief: the future of genomic medicine belongs to platforms that combine automation, adaptability, and intelligence. 

Stay tuned as we unveil the next chapter of VITALE — and thank you to everyone who visited our poster presentation!

​​​​The Project with the proposal number ENTERPRISES/0223/Sub-Call1/105 and project acronym VITALE is funded by the European Union Recovery and Resilience Facility of the NextGenerationEU instrument, through the Ίδρυμα Έρευνας και Καινοτομίας/Research and Innovation Foundation.